ARID1A and cancer: Despite the apparent high frequency of ARID1A mutations from the TCGA database in some primary tumors such as pancreatic (8.8%), stomach (7.3%), and endometrial (44.4%), BAF250 was initially noted to be infrequently silenced in cancer cell lines (96).